Drug Trial Radar · NCT05904717
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 8, 2023
Primary completion
Jul 31, 2026
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- SyntaraIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to investigate the safety and efficacy of PXS-4728A as an intervention therapy in participants with iRBD. This study will be conducted in participants aged 50 to 80 years of age and will investigate a single dose level.
Conditions
- REM Sleep Behavior Disorder
Interventions
PXS-4728 (A)Drug
Participants will receive once daily (QD) for period of 12 weeks
Matching Placebo (B)Drug
Participants will receive once daily (QD) for period of 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the reduction of microglial activation across striato-cortical regionsTime frame: Up to Week 12
- To assess the safety and tolerability of PXS-4728A as determined by adverse events (AEs)Time frame: Up to Week 24
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Parkinsons Disease Research Clinic - Macquarie University
Macquarie, New South Wales, Australia
Cognitive Neuroscience Brain & Mind Centre
Camperdown, Sydney, Australia
Clinical Neuroscience Nuffield Department of Clinical Neurosciences
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.